Article
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
Oncotarget - 29 Sept 2015
Tiffen Jessamy C, Gunatilake Dilini, Gallagher Stuart J, Gowrishankar Kavitha, Heinemann Anja, Cullinane Carleen, Dutton-Regester Ken, Pupo Gulietta M, Strbenac Dario, Yang Jean Y, Madore Jason, Mann Graham J, Hayward Nicholas K, McArthur Grant A, Filipp Fabian V, Hersey Peter
Abstract excerpt
The epigenetic modifier EZH2 is part of the polycomb repressive complex that suppresses gene expression via histone methylation. Activating mutations in EZH2 are found in a subset of melanoma that contributes to disease progression by inactivating tumor suppressor genes. In this study we have targeted EZH2 with a specific inhibitor (GSK126) or depleted EZH2 protein by stable shRNA knockdown. We show that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.